The US Food and Drug Administration (FDA) has approved orforglipron (Foundayo; Eli Lilly and Company) for chronic weight management in adults with obesity, or in adults with overweight and at least 1 weight-related comorbidity — expanding the oral GLP-1 receptor agonist (GLP-1 RA) landscape and offering primary care physicians a new prescribing option that does not require fasting before administration.¹

The agency's decision, announced April 1, 2026, is based on data from the ATTAIN phase 3 global clinical development program, which enrolled more than 4,500 participants across 2 registration trials.¹ Orforglipron is a small-molecule, nonpeptide GLP-1 RA — a mechanistic distinction from the peptide-based oral semaglutide (Rybelsus; Novo Nordisk), which must be taken on an empty stomach with no more than 4 oz of plain water, followed by a mandatory 30-minute fast before eating, drinking, or taking other oral medications.²

A Decades-Long Road to an Oral Obesity Medicine

The GLP-1 RA class has undergone substantial evolution since the FDA approved the first agent, exenatide (Byetta), in 2005 for the treatment of type 2 diabetes (T2D).³ It was not until 2014 that the first GLP-1 RA — liraglutide (Saxenda; Novo Nordisk) — received an indication specifically for obesity management, followed by the landmark 2021 approval of subcutaneous semaglutide 2.4 mg (Wegovy; Novo Nordisk).³ The approval of Wegovy was supported by the STEP-1 trial, which demonstrated mean weight loss of 14.9% at 68 weeks vs 2.4% with placebo — results that, at the time, were described as approaching those seen with bariatric surgery.⁴

Despite the clinical efficacy of injectable GLP-1 RAs, access gaps have remained substantial. According to Lilly chair and CEO David A. Ricks, fewer than 1 in 10 people who could benefit from a GLP-1 RA are currently taking one, held back by factors including access barriers, stigma, and the perception that their condition is not serious enough to warrant treatment.¹

That unmet need persists against a persistent backdrop of high US obesity prevalence. According to the National Center for Health Statistics, approximately 40.3% of US adults had obesity during August 2021–August 2023, with the highest rates observed in adults aged 40 to 59 years.⁵ At least 1 in 4 adults in every US state is currently living with obesity, and in 23 states, the prevalence exceeds 35% — a threshold that no state had crossed before 2013.⁶

ATTAIN-1 Trial Results

The pivotal ATTAIN-1 trial (NCT05869903) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled study evaluating once-daily orforglipron at doses of 6 mg, 12 mg, and 36 mg vs placebo in 3,127 adults with obesity, or overweight with at least 1 comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), without diabetes.¹,⁷

Full results were published in the New England Journal of Medicine in September 2025.⁷ At 72 weeks, mean percent body weight changes from baseline were −7.5% (95% CI, −8.2 to −6.8) with 6 mg, −8.4% (95% CI, −9.1 to −7.7) with 12 mg, and −11.2% (95% CI, −12.0 to −10.4) with 36 mg of orforglipron, compared with −2.1% (95% CI, −2.8 to −1.4) with placebo (P <.001 for all comparisons).⁷ Using the efficacy estimand — representing outcomes had all participants remained on treatment without initiating prohibited weight management therapies — participants taking the highest dose lost an average of 27.3 lb (12.4%), vs 2.2 lb (0.9%) with placebo.¹

Among participants in the 36-mg group, 54.6% achieved a body weight reduction of 10% or more, 36.0% achieved 15% or more, and 18.4% achieved 20% or more, compared with 12.9%, 5.9%, and 2.8% in the placebo group, respectively.⁷ Orforglipron treatment also produced improvements in key cardiometabolic risk factors across all doses, including waist circumference, systolic blood pressure, non-HDL cholesterol, and triglycerides.¹ The ATTAIN-1 investigators noted that cardiometabolic improvements were similar to those reported with oral and injectable semaglutide in obesity trials, despite the modestly lower degree of weight loss observed.⁷

The ATTAIN-2 trial (NCT05872620), evaluating orforglipron in more than 1,600 adults with obesity or overweight and T2D, was published in The Lancet in November 2025. FDA approval for orforglipron in T2D has not yet been granted; Lilly has indicated a US submission is planned.⁸

Adverse events leading to treatment discontinuation occurred in 5.3% to 10.3% of participants across orforglipron dose groups, compared with 2.7% in the placebo group. The most common adverse events were gastrointestinal in nature, consistent with the established class profile.⁷

"People living with obesity need treatment options that meet them where they are — and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment," said Deborah Horn, DO, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston. "With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials — addressing both the clinical realities of obesity and the practical challenges patients face every day."¹

Mechanism and Formulation Context

Orforglipron was discovered by Chugai Pharmaceutical Co, Ltd and licensed by Lilly in 2018. Its nonpeptide, small-molecule structure enables oral bioavailability without the absorption enhancers — such as salcaprozate sodium (SNAC) — required by peptide-based oral GLP-1 RAs. The SNAC co-formulation in oral semaglutide necessitates strict fasting conditions because food and beverages other than a small volume of plain water substantially reduce semaglutide absorption; only approximately 0.4% to 1% of each oral semaglutide dose is absorbed under optimal conditions.²,⁹ Orforglipron's small-molecule design circumvents this pharmacokinetic limitation, allowing ingestion at any time of day with or without food.¹

Beyond weight management, orforglipron is under active investigation for T2D, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, and stress urinary incontinence.¹

Safety Considerations

The prescribing information for orforglipron carries a boxed warning regarding the potential for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), consistent with the class warning shared by all GLP-1 RAs. Orforglipron is contraindicated in patients with a personal or family history of MTC, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or prior serious hypersensitivity to orforglipron or any of its ingredients.¹

Serious adverse effects include pancreatitis, severe gastrointestinal problems, dehydration-related kidney injury, hypoglycemia (particularly in patients also receiving insulin or a sulfonylurea), serious allergic reactions, gallbladder disease, and an increased risk of pulmonary aspiration in patients undergoing procedures under anesthesia or deep sedation. The most common adverse effects are nausea, constipation, diarrhea, vomiting, indigestion, and abdominal pain.¹

Orforglipron should not be used concurrently with other GLP-1 RAs. Because orforglipron may reduce the efficacy of oral hormonal contraceptives, clinicians should advise patients to use an alternative or additional contraceptive method for 30 days after initiation and for 30 days after each dose increase. The drug is not recommended during pregnancy or breastfeeding, and safety and efficacy in pediatric patients have not been established.¹

Orforglipron is available in oral tablets at 6 doses: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. It is available via LillyDirect with free home delivery, and will be accessible through US retail pharmacies and telehealth providers. Eligible patients with commercial insurance may pay as little as $25 per month with a Lilly savings card; self-pay pricing starts at $149 per month for the lowest dose, and eligible Medicare Part D beneficiaries may access the drug for $50 per month beginning July 1, 2026.¹

References

1. Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. News release. April 1, 2026. Accessed April 1, 2026. www.lilly.com
2. Rybelsus (semaglutide) tablets. Prescribing Information. Novo Nordisk; 2024. Accessed April 1, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf
3. Innovative Rx Strategies. Rx history: The rise of GLP-1s. Accessed April 1, 2026. https://innovativerxstrategies.com/rx-history-glp1s/
4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
5. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023. NCHS Data Brief, no. 508. National Center for Health Statistics; 2024. doi:10.15620/cdc/159281
6. Centers for Disease Control and Prevention. New CDC data show adult obesity prevalence remains high. News release. September 12, 2024. Accessed April 1, 2026. https://www.cdc.gov/media/releases/2024/p0912-adult-obesity.html
7. Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774
8. Lilly. What to know about orforglipron. Accessed April 1, 2026. https://www.lilly.com/news/stories/what-to-know-about-orforglipron
9. Ma X, Liu R, Pratt EJ, et al. Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist. Diabetes Ther. 2024;15(4):819-832. doi:10.1007/s13300-024-01554-1